Cargando…
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
BACKGROUND: Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti–epidermal growth factor receptor (EGFR) and anti–vascular...
Autores principales: | Dell’Aquila, Emanuela, Zeppola, Tea, Stellato, Marco, Pantano, Francesco, Scartozzi, Mario, Madaudo, Cristina, Pietrantonio, Filippo, Cremolini, Chiara, Aprile, Giuseppe, Vincenzi, Bruno, Moretto, Roberto, Puzzoni, Marco, Garattini, Silvio Ken, Lobefaro, Riccardo, Tonini, Giuseppe, Santini, Daniele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412900/ https://www.ncbi.nlm.nih.gov/pubmed/32821190 http://dx.doi.org/10.1177/1179554920946693 |
Ejemplares similares
-
Prognostic and predictive factors in pancreatic cancer
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020) -
Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020) -
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022) -
Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019) -
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)